Dipeptidyl Peptidase 4 Inhibitors and the Risk of Cardiovascular Disease in Patients with Type 2 Diabetes: A Tale of Three Studies

Dipeptidyl Peptidase 4 Inhibitors and the Risk of Cardiovascular Disease in Patients with Type 2 Diabetes: A Tale of Three Studies

Item
http://www.wikidata.org/entity/Q26777177
The regulatory role of DPP4 in atherosclerotic disease.Cardiovascular efficacy of sitagliptin in patients with diabetes at high risk of cardiovascular disease: a 12-month follow-up.Sitagliptin and risk of heart failure hospitalization in patients with type 2 diabetes on dialysis: A population-based cohort study.Transcriptomic alterations in the heart of non-obese type 2 diabetic Goto-Kakizaki ratsPlasma DPP4 activity is associated with no-reflow and major bleeding events in Chinese PCI-treated STEMI patients.Vildagliptin reduces plasma stromal cell-derived factor-1α in patients with type 2 diabetes compared with glimepiride.Assessment of the Risk of Hospitalization for Heart Failure With Dipeptidyl Peptidase-4 Inhibitors, Saxagliptin, Alogliptin, and Sitagliptin in Patients With Type 2 Diabetes, Using an Alternative Measure to the Hazard Ratio.DPP4 inhibitors and cardiovascular outcomes: safety on heart failure.Treating Diabetes in Patients with Heart Failure: Moving from Risk to Benefit.Dipeptidyl peptidase-4 inhibitors and cancer risk in patients with type 2 diabetes: a meta-analysis of randomized clinical trials.High circulating plasma dipeptidyl peptidase- 4 levels in non-obese Asian Indians with type 2 diabetes correlate with fasting insulin and LDL-C levels, triceps skinfolds, total intra-abdominal adipose tissue volume and presence of diabetes: a case-cSodium Glucose Cotransporter-2 Inhibition in Heart Failure: Potential Mechanisms, Clinical Applications, and Summary of Clinical Trials.Postmeal increment in intact glucagon-like peptide 1 level, but not intact glucose-dependent insulinotropic polypeptide levels, is inversely associated with metabolic syndrome in patients with type 2 diabetes.Effects of a Dipeptidyl Peptidase 4 Inhibitor Sitagliptin on Glycemic Control and Lipoprotein Metabolism in Patients with Type 2 Diabetes Mellitus (GLORIA Trial).Dipeptidyl peptidase-4 inhibitors and incidence of inflammatory bowel disease among patients with type 2 diabetes: population based cohort study.Coadministration of DPP-4 inhibitor and insulin therapy does not further reduce the risk of cardiovascular events compared with DPP-4 inhibitor therapy in diabetic foot patients: a nationwide population-based study
P2860

Dipeptidyl Peptidase 4 Inhibitors and the Risk of Cardiovascular Disease in Patients with Type 2 Diabetes: A Tale of Three Studies

Item
http://www.wikidata.org/entity/Q26777177
description
2015 nî lūn-bûn
@nan
2015 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Dipeptidyl Peptidase 4 Inhibit ...... betes: A Tale of Three Studies
@ast
Dipeptidyl Peptidase 4 Inhibit ...... betes: A Tale of Three Studies
@en
Dipeptidyl Peptidase 4 Inhibit ...... betes: A Tale of Three Studies
@nl
type
label
Dipeptidyl Peptidase 4 Inhibit ...... betes: A Tale of Three Studies
@ast
Dipeptidyl Peptidase 4 Inhibit ...... betes: A Tale of Three Studies
@en
Dipeptidyl Peptidase 4 Inhibit ...... betes: A Tale of Three Studies
@nl
prefLabel
Dipeptidyl Peptidase 4 Inhibit ...... betes: A Tale of Three Studies
@ast
Dipeptidyl Peptidase 4 Inhibit ...... betes: A Tale of Three Studies
@en
Dipeptidyl Peptidase 4 Inhibit ...... betes: A Tale of Three Studies
@nl
P1433
P1476
P2093
P2860
P304
P31
P3181
P356
P407
P433
P478
P50
P577
P5875
P698
P921
P932
P3181
P356
P1433
P1476
Dipeptidyl Peptidase 4 Inhibit ...... betes: A Tale of Three Studies
@en
P2093
P2860
P304
P31
P3181
P356
P407
P433
P478
P50
P577
P5875
P698
P921
P932